Abbott Laboratories Corporation

David J Bacino

Leslie A Freiberg

John S Tadanier

Larry L Klein

Robert Hallas

Carla M Edwards

Clinton M Yeung

Erythromycin derivatives

Disclosed herein are erythromycin derivatives of the formula ##STR1## wherein R.sub.1 is lower alkyl, aryl, alkene, aryl halide, alkylamino, hydroxyalkyl and furanyl, and pharmaceutically acceptable salts thereof. These compounds have improved oral absorption, reduced effects on gastrointestinal motility, increased acid stability and longer serum half-lives.

Erythromycin A 11,12-carbonates and method of use

Disclosed herein are fortimicin derivatives represented by the formula: ##STR1## wherein R is hydrogen, loweralkyl, aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl, hydroxyloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N,N-diloweralkylaminohydroxyloweralkyl, loweracyl, aminoloweracyl, diaminoloweracyl, hydroxyloweracyl, N-loweralkylaminoloweracyl, N,N-diloweralkylaminoloweracyl, or aminohydroxyloweracyl, and the pharmaceutically acceptable salts thereof. Also disclosed are intermediates useful in the preparation of these compounds and compositions of these compounds together with a pharmaceutically acceptable carrier and/or diluent.

3-Amino-3-demethoxyfortimicins, pharmaceutical compositions thereof and

Growing community of inventors

Waukegan, IL, United States of America

David J Bacino